Immune System Cancer Attack
-
{
- All
- News
-
Unexpected Immune System Mechanism Found To Attack Cancer, Scientists Reveal
- Friday June 5, 2026
- Health | Written by Sambhav Kumar
Many modern cancer treatments, including immunotherapy, depend on activating killer T cells to recognise and destroy tumours.
-
www.ndtv.com
-
Which Cancers Does Keytruda Work On? Apollo Oncologists Explain Effectiveness
- Saturday April 18, 2026
- Health | Written by Debosmita Ghosh
The Drug Controller General of India (DCGI) has approved Keytruda for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
www.ndtv.com
-
High Cost, Limited Access: How Counterfeit Keytruda Market Puts Cancer Patients At Risk
- Tuesday April 21, 2026
- Health | Written by Tanushka Dutta
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune system identify and attack cancer cells.
-
www.ndtv.com
-
Oncologists Explain Why They Prescribe Keytruda To Cancer Patients, When And How It Works
- Tuesday April 14, 2026
- Health | Written by Debosmita Ghosh
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
www.ndtv.com
-
What Is Imfinzi Durvalumab, The Cancer Drug That Just Got Approval For Use In India?
- Wednesday February 11, 2026
- Health | Written by Varsha Vats
Unlike traditional chemotherapy, which attacks rapidly dividing cells (both healthy and cancerous), Durvalumab helps your own immune system recognise and destroy cancer cells. It targets a specific protein called PD-L1.
-
www.ndtv.com
-
New Antibody Treatment Boosts Immune Response Against Tumor: Study
- Tuesday November 12, 2024
- World News | Indo-Asian News Service
Israeli researchers and their colleagues from the United States developed an antibody-based treatment that empowers the body's immune system to effectively attack cancer cells and prevent their spread, Israel's Weizmann Institute of Science said.
-
www.ndtv.com
-
New Drug Found Effective Against Aggressive Bladder Cancer
- Monday June 6, 2016
- Health | Press Trust of India
A new drug that harnesses the immune system to attack tumours is highly effective against advanced bladder cancer, researchers, including one of Indian-origin, have found.
-
www.ndtv.com
-
Suicide Gene Therapy Kills Prostate Cancer Cells
- Sunday December 13, 2015
- Health | Indo-Asian News Service
Combining radiation treatment with 'suicide gene therapy' - a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them - provides an effective two-pronged punch against the disease, new research shows.
-
www.ndtv.com
-
Immunotherapy May Work in Many Cancers: Study
- Friday May 9, 2014
- World News | Agence France-Presse
An experimental therapy that helps retrain a patient's own immune system to attack tumors may work in a wide range of common cancers, according to a preliminary US study Friday.
-
www.ndtv.com
-
Unexpected Immune System Mechanism Found To Attack Cancer, Scientists Reveal
- Friday June 5, 2026
- Health | Written by Sambhav Kumar
Many modern cancer treatments, including immunotherapy, depend on activating killer T cells to recognise and destroy tumours.
-
www.ndtv.com
-
Which Cancers Does Keytruda Work On? Apollo Oncologists Explain Effectiveness
- Saturday April 18, 2026
- Health | Written by Debosmita Ghosh
The Drug Controller General of India (DCGI) has approved Keytruda for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
www.ndtv.com
-
High Cost, Limited Access: How Counterfeit Keytruda Market Puts Cancer Patients At Risk
- Tuesday April 21, 2026
- Health | Written by Tanushka Dutta
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune system identify and attack cancer cells.
-
www.ndtv.com
-
Oncologists Explain Why They Prescribe Keytruda To Cancer Patients, When And How It Works
- Tuesday April 14, 2026
- Health | Written by Debosmita Ghosh
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
www.ndtv.com
-
What Is Imfinzi Durvalumab, The Cancer Drug That Just Got Approval For Use In India?
- Wednesday February 11, 2026
- Health | Written by Varsha Vats
Unlike traditional chemotherapy, which attacks rapidly dividing cells (both healthy and cancerous), Durvalumab helps your own immune system recognise and destroy cancer cells. It targets a specific protein called PD-L1.
-
www.ndtv.com
-
New Antibody Treatment Boosts Immune Response Against Tumor: Study
- Tuesday November 12, 2024
- World News | Indo-Asian News Service
Israeli researchers and their colleagues from the United States developed an antibody-based treatment that empowers the body's immune system to effectively attack cancer cells and prevent their spread, Israel's Weizmann Institute of Science said.
-
www.ndtv.com
-
New Drug Found Effective Against Aggressive Bladder Cancer
- Monday June 6, 2016
- Health | Press Trust of India
A new drug that harnesses the immune system to attack tumours is highly effective against advanced bladder cancer, researchers, including one of Indian-origin, have found.
-
www.ndtv.com
-
Suicide Gene Therapy Kills Prostate Cancer Cells
- Sunday December 13, 2015
- Health | Indo-Asian News Service
Combining radiation treatment with 'suicide gene therapy' - a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them - provides an effective two-pronged punch against the disease, new research shows.
-
www.ndtv.com
-
Immunotherapy May Work in Many Cancers: Study
- Friday May 9, 2014
- World News | Agence France-Presse
An experimental therapy that helps retrain a patient's own immune system to attack tumors may work in a wide range of common cancers, according to a preliminary US study Friday.
-
www.ndtv.com